PlainPharmaWatch

CMS Open Payments · Program Year 2024

LumiraDx, Inc.

LumiraDx, Inc. reported $600.00 across General Payments, Research, and Ownership to 2 physicians and teaching hospitals across 2 transactions.

See the rankings → How this is sourced
$600.00 Below-median payer
All-tracks total
2 Below-median volume
Transactions
2 Below-median reach
Recipients
#1872
of 1,925 companies

LumiraDx, Inc. reported $600.00 across all CMS Open Payments tracks (General + Research + Ownership) to 2 physicians and teaching hospitals in Program Year 2024 - ranking #1872 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $600.00, averaging $300.00 per recipient.

LumiraDx, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

10/100

Total payments

F

10/100

Transaction volume

F

10/100

Physician reach

F

10/100

Payment type diversity

F

10/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer lumiradx-inc LumiraDx, Inc.

$600.00 · #1872/1,925 · 0.0% industry · PY2024

  • TOT $600.00
  • RANK #1872
  • SHARE 0.0%
  • TXN 2
  • RCP 2
  • CAT 1
  • GEN $600.00
  • TOP1 50.0%
  • PY 2024

Volume peers

Nearest volume peer: Pixee Medical Inc. ($601.00)

Cook Biotech Incorporated$609.12Pixee Medical Inc.$601.00LumiraDx, Inc. (this)$600.00Vantage Technology LLC$593.80R-Pharm US LLC$588.45
All-tracks payment totals near LumiraDx, Inc. (CMS Open Payments PY2024)

LumiraDx, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for LumiraDx, Inc.

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For LumiraDx, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

Of the 1 general-payment categories charted below, "Consulting Fee" is the largest at $600.00 across 2 transactions, 100.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads LumiraDx, Inc.'s 1-category general-payment breakdown at $600.00, 100.0% of the reported total.

How LumiraDx, Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$600.00
Payment Type Amount Transactions
Consulting Fee $600.00 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $600.00 (100.0%) of $600.00 in this company's General Payments records across 2 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for LumiraDx, Inc.

The five named recipients with the highest reported General Payments from this company

Christopher Defilippi$300.00Allan Jaffe$300.00
  1. 1

    Christopher Defilippi

    $300.00 across 1 reported transactions

  2. 2

    Allan Jaffe

    $300.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

LumiraDx, Inc. ranks #1872 of 1,925 by total payments (bottom 3% by spend) but is notably more concentrated than that alone would suggest -- #370 of 1,838 by HHI (top 20% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.

00.30.50.81.14964.34973.94983.54993.15002.8Total payments ($M)Concentration (HHI, 0-10,000)
LumiraDx, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as LumiraDx, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about LumiraDx, Inc..

STORZ MEDICAL America, Inc.

HHI 5000

OTU Medical Inc.

HHI 5000

SmartPractice Allergen Bank, L.L.C.

HHI 5000

Mobius Therapeutics, LLC

HHI 5000

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with LumiraDx, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

LumiraDx, Inc. ranks #1872 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download LumiraDx, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.